Liladroscontinu (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

The combination suppresses the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, thereby inhibiting ovulation. Drospirenone also thickens cervical mucus, while both agents alter the endometrial lining, reducing the chance of fertilisation and implantation.

The dosing regimen is set by the prescribing healthcare professional. Typically, a course consists of a series of active tablets taken once daily for a defined number of days, followed by a placebo or hormone‑free interval, as directed by the prescriber.

Liladroscontinu is contraindicated during pregnancy and should not be started in women who are pregnant. It is generally not recommended for use while breastfeeding; women should consult their healthcare provider for alternative contraception if they are nursing.

To order Liladroscontinu, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Liladroscontinu offers efficacy comparable to other combined oral contraceptives. Its progestin component, drospirenone, has anti‑mineralocorticoid activity, which may result in a lower risk of water retention and related side effects compared with some other progestins such as levonorgestrel.

Store Liladroscontinu at ambient temperature below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed when not in use.

Liladroscontinu is taken orally, usually one tablet each day at the same time, with or without food. The regimen follows a fixed schedule of active tablets followed by a hormone‑free interval, as prescribed by the healthcare professional.

Serious risks include venous thromboembolism, arterial thrombosis, hypertension, liver disorders such as hepatic adenoma, and severe allergic reactions. Patients should be educated to seek immediate medical attention if they experience symptoms such as leg pain, chest discomfort, severe headache, or rash.

Women who are pregnant, have a history of thromboembolic disease, uncontrolled hypertension, known hypersensitivity to any component, or who are smokers over the age of 35 should avoid using Liladroscontinu. A thorough medical assessment is required before initiating therapy.